Intellectual Property (IP) can be sold, licensed and mortgaged like any other property asset. The ability to out-licence and/or in-licence IP is often crucial for life science companies seeking to develop and commercialise innovative medicines, devices and services. This may for example be to provide freedom to operate, or access to essential expertise and resources. This guidance note seeks to provide an overview of licencing IP, with particular emphasis on patents, and why any life science IP filing and exploitation strategy should include consideration of potential future licensing activities . . .
This content is restricted to subscribers. To view this content please register an account.
If you are already a subscriber, please login below.